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Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes
and has been implicated in the transformation of human cells. Analysis of
the cytological and anti-tumor activities of BI 2536, a novel, selective
pharmacological inhibitor of Plk1, has connected chemistry and biology
to the bedside.Simon Plyte1
and Andrea Musacchio2
In the time it takes you to read two
recent papers by Lenart et al. [1]
and Steegmaier et al. [2], several
thousand cells in your body will
have successfully undergone
mitosis, during which a mother cell
containing a replicated genome
divides into two (usually identical)
daughter cells. Mitosis involves
a superbly choreographed dance
whereby the mitotic spindle, one
of nature’s more beautiful
macromolecular structures, seeks,
captures, aligns, verifies and then
separates the chromosome
partners in a wonderfully elegant
process, orchestrated by several
protein kinases. The
circumstances for mitotic entry are
set by the ignition of a protein
kinase called Cdk1 (Figure 1A). The
Cdk1 engine keeps running until all
chromosomes have established
solid connections with the spindle.
At that point, the key is removed
from the engine (Cyclin B, the
Cdk1 activator, is degraded), an
event that promotes chromosome
partition and mitotic exit,
heralding the birth of two new
cells [3].
A mitotic cell swarms with
activity. Phenomena such as
chromosome condensation,
kinetochore and spindle assembly,
and the formation of microtubule
bundles stably connecting the
chromosomes to the spindle, all
occur within minutes and are
essential for the error-free partitionof the genetic material (Figure 1A).
Accuracy in these processes is
essential to maintain euploidy in
normal cells, and accordingly,
safety devices have developed to
monitor these events and ensure
their seamless execution [3].
The mitotic cell division process,
however, is a phase of vulnerability
not only for normal cells, but for
cancer cells, too. The papers from
Lenart et al. [1] and Steegmaier
et al. [2] provide a stunning
demonstration that as cancer
cells navigate their way through
mitosis, they are susceptible to an
ambush. The work is the fruit of an
academic-industrial collaboration
and describes the use of BI 2536,
a small-molecule inhibitor of
polo-like kinase 1 (Plk1), as an
analytical tool and potential cancer
theraputic. The studies delineate
some of the pleiotropic functions
attributed to Plk1 in mitosis and
demonstrate that inhibition of Plk1
function translates into significant
anti-tumor activity in vivo.
Like Cdk1, Plk1 is a protein
kinase [4], and as such utilizes ATP
to add phosphate groups onto
substrates, thereby potentially
influencing the activity, stability, or
subcellular localization of specific
protein targets. In the last fifteen
years, the pharmaceutical industry
has developed an obsessive
passion for the attenuation of
protein kinases, as these enzymes
are implicated in the control of
almost every biological process.
The ATP-binding pocket of protein
kinases represents an ideal site forthe binding of small-molecule
inhibitors, and several classes of
ATP-mimetic compounds, of which
BI 2536 is an excellent example, are
being investigated for their
potential to inhibit a plethora of
protein kinases [5]. Besides
Cdk1 and Plk1, several other
mitotic kinases display their
regulatory influence on the
mitotic scene – most notably the
Aurora A and Aurora B kinases [6].
Both Plk1 and the Aurora kinases
have long been recognized as
potential targets for cancer
therapy, and numerous
small-molecule inhibitors of Aurora
kinases are currently undergoing
clinical development. It appears
that Polo-like kinase inhibitors
have now joined the race to
become blockbuster anti-cancer
drugs [7,8].
Understanding how these drugs
work to kill cells is very important.
For example, taxanes work by
preventing the depolymerization of
microtubules, and this, among
other things, prevents the
assembly of a functional mitotic
spindle, leading to cell death [9].
However, inhibition of microtubule
function is detrimental to several
cellular processes, including
axonal transport and cell
movement, and as a result there are
several mechanisms of cell death in
response to taxane treatment,
including apoptosis, mitotic
catastrophe, lytic necrosis, and
induced senescence. More
recently, inhibitors of Eg5, a kinesin
motor protein, have entered clinical
trials. These agents should disrupt
microtubule dynamics in
a mitosis-specific manner. The
mechanism of cell death here is
predominantly apoptotic and can
be induced rapidly from within
mitosis or after slippage into an
abnormal G1 phase by a
p53-dependent mechanism [9].
The first-generation Aurora
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Figure 1. Pleiotropic functions of Plk1.
(A) Mitosis separates the G2 phase of a mother cell from the G1 phase of two daughter cells. Based on morphological criteria, the
process has been traditionally divided into five phases (Prophase to Telophase) [1]. Centrosome separation is mandatory to form
a bipolar spindle. Spindle microtubules bind chromosomes at kinetochores, complex protein disks that form on centromeric DNA.
When chromosomes are aligned at the metaphase plate, the spindle assembly checkpoint is switched off, Cyclin B is degraded,
and loss of cohesion between sister chromatids results in the segregation of chromosomes to the daughter cells. Plk1 controls sev-
eral aspects of mitosis. In the white box, we report events in which Plk1 function (bold) has been implicated; under these are known
Plk1 substrates involved in those events [4]. (B) Addition of BI 2536 perturbs the events shown in panel (A). Prophase is prolonged,
possibly due to difficulties in activating Cdk1-Cyclin B. Centrosome maturation and separation are hampered, so that a monoastral
spindle is formed rather than a bipolar one. This leads to a chronic activation of the spindle assembly checkpoint and to cell death
without ever exiting mitosis. Other anti-mitotics result in different patterns of cell damage and cell death that might be important for
toxicity and efficacy during anti-tumor therapy (see text for details).Aurora A and Aurora B. Inhibition of
Aurora A results in a mitotic arrest
with monopolar spindles, while
inhibition of Aurora B causes
silencing of the SAC and mitotic
exit without chromosome
separation [10–12]. Precocious
mitotic exit with defective
cytokinesis and polyploidy is the
predominant phenotype with these
dual inhibitors. This raises some
concern regarding the long-term
implications of inhibiting Aurora B
in normal cycling cells. Polyploidy
has been shown to facilitatetransformation [13], and the
accumulation of polyploid cells
during therapy might be expected
to result in secondary tumors.
How does BI 2536 kill cells?
Lenart and co-workers [1] analyzed
the effects of BI 2536 on mitotic
progression of HeLa cells, a widely
used cellular model to study
mitosis. As the succession of
events is very rapid in mitosis,
a small chemical like BI 2536 with
specific inhibitory effects provides
an invaluable tool to perform
razor-sharp dissectionexperiments requiring fast
temporal resolution. In a nutshell,
BI 2536 caused a prometaphase
arrest due to severe perturbation of
normal mitotic progression,
followed by mitotic catastrophe,
a form of cell death taking place
from within mitosis (Figure 1B).
The precise causes of mitotic
catastrophe (that is, the actual
offences that trigger this type of
cell death) are largely unclear. Its
occurrence in the presence of BI
2536, however, is undoubtedly
the basis for the efficacy of this
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cancer, as described by
Steegmaier et al. [2]. Mitotic
entrapment and subsequent cell
death translated into significant
growth inhibition in a wide range of
tumor cell lines. More strikingly, BI
2536 demonstrated a remarkable
efficacy in vivo in several tumor
xenograft models and even caused
regression of large tumors. How
these in vivo efficacieswill translate
to the clinic, where tumors are
more heterogeneous, remains to
be seen. Given that cell death
occurs predominantly from
mitosis, with almost no polyploid
progeny, the undesired effects of
other anti-mitotic agents should be
reduced with Plk-1 inhibitors.
The reason why different
anti-mitotics result in so many
different mechanisms of cell death
remains unclear. Chemical biology
analyses like the one reported by
Lenart et al. [1] can help shed light
on this mystery, and the reader is
referred to this paper for a full
description of the cellular
phenotypes caused by BI 2536.
In short, the investigation covers
the roles of Plk1 in cell cycle
progression and in mitosis. Several
effects of inhibiting Plk1 have been
described in previous papers,
including a number of recent
chemical biology analyses
[4,14,15]. Lenart et al. [1]
summarize and extend these
previous observations, providing
a beacon for those wishing to
understand the cellular function of
Plk1. A particular advantage
revealed in the new work is the
remarkable potency and selectivity
of BI 2536 (0.8 nM) towards Plk1.
Lenart et al. [1] report that HeLa
cells treated with BI 2536 were first
delayed in prophase (Figure 1B),
consistent with a role for Plk1 in the
activation of the CDK1-Cyclin B
complex [4]. After reluctantly
entering mitosis, cells became
blocked in prometaphase with
aberrant monopolar spindles
that failed to attach stably to
chromosomes [1]. The
prometaphase arrest was
maintained by the spindle
assembly checkpoint (SAC),
a safety device that monitors the
attachment of microtubules to
mitotic chromosomes [16]. SAC
activity results in the stabilizationof Cyclin B, which in turn prolongs
CDK1 activity to maintain the
mitotic state. Aficionados ofmitotic
affairs will be interested in reading
that in agreement with previous
results [17,18], BI 2536 blocked the
degradation of the early mitotic
inhibitor Emi1 [1]. Nonetheless,
the degradation of Cyclin A took
place normally, showing that the
degradation of Emi1 is not
a prerequisite for degrading Cyclin
A. This also rules out the possibility
that the prometaphase arrest
caused by BI 2536 depends on
failure to degrade Cyclin A, which
has been previously shown to
prevent mitotic exit [19]. Another
remarkable observation made
possible by the use of
small-molecule inhibitors is that
the activity of Plk1 is required not
only to obtain, but also to maintain,
chromosome bi-orientation on the
mitotic spindle [1,15].
Recently, with the success of the
broad-spectrum kinase inhibitor
Sunitinib [20], the paradigm for
receptor tyrosine kinase inhibitors
has shifted toward the notion of
‘‘dirty is good for efficacy,’’
because multi-kinase inhibition is
probably required to successfully
combat the adaptability and
flexibility of mitogenic signal
transduction in uncontrolled
cancer cells. Further, in contrast to
original fears, these compounds
demonstrate that some ‘broad
spectrum’ kinase inhibitors can
have manageable toxicities in the
clinic. But mitosis, compared to
mitogenic signal transduction, is
hard-wired and tightly controlled,
and to guarantee fidelity of the
process, has little or no
redundancy afforded in its
orchestration. With this in mind, it
would seem that good potency and
selectivity probably contribute
significantly to the observed
efficacy of BI 2536. High selectivity
is probably required to prevent
cancer cells from getting ‘held up’
in other phases of the cell cycle,
thereby allowing them to go
running headlong into the
mitotic trap. Potent Plk1 inhibition
ensures a prolonged arrest in
prometaphase, effectively
springing the trap and ultimately
leading to cell death (Figure 1B).
Possibly, Plk1 inhibitors are
bringing the kinase-inhibitorparadigmback toward the idea that
‘‘clean is good’’ – at least for mitotic
inhibitors.
In summary, BI 2536 defines
a new anti-proliferation mechanism
of action that will undoubtedly lead
to a different spectrum of tumor
efficacies and toxicities compared
to the Aurora inhibitors and existing
anti-mitotic agents. The authors
report that BI 2536 was well
tolerated in their mice studies, and
early results from Phase I clinical
trials have revealed neutropenia
(loss of neutrophils) as the
dose-limiting toxicity [2]. This is
expected for a potent anti-mitotic
agent. In contrast to Aurora
inhibitors, which generated great
excitement, the first Plk1 inhibitor
has slid quietly into clinical trials,
and early results look promising.
Inhibitors of both kinase families,
with their different mechanisms of
action, hold much promise for the
treatment of a wide range of human
cancers, and we wait with great
expectations for the results from
clinical trials.
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Tropical forests are disappearing
at a rapid rate while the remnants
face an increasing number of
threats [1]. Although a growing
number of studies [2–6] have
addressed the effects of forest
fragmentation on tropical bird
communities, most have had to
draw inferences from species
distribution patterns, rather than
examine colonization and
extinction dynamics directly [5,6].
Two recent mark-recapture studies
[7,8] are welcome exceptions.
Contrary to expectations [4,6],
these new studies [7,8] show that,
not only can tropical forest
understory birds (Figure 1)
disperse long distances, but their
need to use large areas may
make mobile species more
susceptible to extinction in
fragments.
The groundbreaking new
findings [7,8] are based on nearly15. Peters, U., Cherian, J., Kim, J.H.,
Kwok, B.H., and Kapoor, T.M. (2006).
Probing cell-division phenotype space
and Polo-like kinase function using
small molecules. Nat. Chem. Biol. 2,
618–626.
16. Musacchio, A., and Hardwick, K.G. (2002).
The spindle checkpoint: structural
insights into dynamic signalling. Nat. Rev.
Mol. Cell Biol. 3, 731–741.
17. Hansen, D.V., Loktev, A.V., Ban, K.H., and
Jackson, P.K. (2004). Plk1 regulates
activation of the anaphase promoting
complex by phosphorylating and
triggering SCFbetaTrCP-dependent
destruction of the APC Inhibitor Emi1.
Mol. Biol. Cell 15, 5623–5634.
18. Moshe, Y., Boulaire, J., Pagano, M., and
Hershko, A. (2004). Role of Polo-like
kinase in the degradation of early mitotic
inhibitor 1, a regulator of the anaphase
promoting complex/cyclosome. Proc.
Natl. Acad. Sci. USA 101, 7937–7942.
19. den Elzen, N., and Pines, J. (2001). Cyclin
A is destroyed in prometaphase and can
delay chromosome alignment and
anaphase. J. Cell Biol. 153, 121–136.logy: Area
in Fragment
highly sensitive to habitat
a monumental Amazonian
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50,000 bird captures from the
Biological Dynamics of Forest
Fragments Project (BDFFP) in the
Brazilian Amazon. With
11 fragments (1–100 hectares)
and 12 intact lowland forest
sites (1–600 hectares) in a
41 kilometer-wide area sampled
over two decades, the extent of this
experiment is unequalled in the
tropics [3,8]. Tom Lovejoy began
Figure 1. Ochre-breasted
Antpitta (Grallaricula flavir-
ostris), a typical tropical
forest understory insecti-
vore.
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DOI: 10.1016/j.cub.2007.02.018this experiment in 1979 by
convincing loggers to set aside
fragments of 1, 10 and 100 hectares
[2,9]. Unlike most fragmentation
studies, pre-fragmentation
sampling enabled natural
abundance estimates to be
made of all species. Fragment size
and distance from intact forest
were precisely controlled.
The BDFFP has produced many
critical insights into avian
responses to fragmentation
[2,3,9,10]. For example, Ferraz et al.
[9] showed that fragments less than
100 hectares lose half their
forest-dependent bird species in
under 15 years, too fast for forest
regeneration to help, and that even
isolated 10,000 hectare fragments
could lose half their species in
a century. Combined with
another study [11], Ferraz et al.
[9] concluded that even a
